X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to discover antibodies for a novel target that enables the delivery of biotherapeutics to the brain for indications in neuroscience.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Recipient: AbCellera
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 11, 2024
Details:
Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.
Lead Product(s): Nusinersen
Therapeutic Area: Genetic Disease Product Name: Spinraza
Highest Development Status: Phase IVProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2024
Details:
Qalsody (tofersen) is an antisense oligonucleotide designed to bind to SOD1 mRNA to reduce SOD1 protein production. The U.S. FDA granted accelerated approval for QALSODY to treat amyotrophic lateral sclerosis in adults who have a mutation in the SOD1 gene.
Lead Product(s): Tofersen
Therapeutic Area: Neurology Product Name: Qalsody
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2024
Details:
Skyclarys (omaveloxolone) is an oral Nuclear factor erythroid-derived 2 (Nrf2) pathway activator. It is approved for the treatment of patients with Friedreich’s ataxia.
Lead Product(s): Omaveloxolone
Therapeutic Area: Genetic Disease Product Name: Skyclarys
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2024
Details:
Under the termination, Neurimmune regained global rights to aducanumab, a recombinant human antibody developed to deplete brain amyloid, for the treatment and prevention of Alzheimer’s disease.
Lead Product(s): Aducanumab
Therapeutic Area: Neurology Product Name: BIIB037
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Neurimmune
Deal Size: $380.0 million Upfront Cash: Undisclosed
Deal Type: Termination January 31, 2024
Details:
Under the termination, Acorda will regain global commercialization rights to Fampyra, a prolonged-release tablet formulation of the drug fampridine (4-aminopyridine, 4-AP or dalfampridine) for adult patients with multiple sclerosis with walking disability.
Lead Product(s): Fampridine
Therapeutic Area: Neurology Product Name: Fampyra
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Acorda Therapeutics
Deal Size: $510.0 million Upfront Cash: $110.0 million
Deal Type: Termination January 11, 2024
Details:
Leqembi (lecanemab-irmb) is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). It is indicated for the treatment of Alzheimer’s disease.
Lead Product(s): Lecanemab-irmb
Therapeutic Area: Neurology Product Name: Leqembi
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Eisai
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2024
Details:
Skyclarys (omaveloxolone) is an oral, once-daily medication indicated for the treatment of Friedreich’s ataxia (FA) in adults and adolescents aged 16 years and older.
Lead Product(s): Omaveloxolone
Therapeutic Area: Genetic Disease Product Name: Skyclarys
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2023
Details:
Skyclarys (omaveloxolone) is an oral Nuclear factor erythroid-derived 2 (Nrf2) pathway activator. It is approved for the treatment of patients with Friedreich’s ataxia.
Lead Product(s): Omaveloxolone
Therapeutic Area: Genetic Disease Product Name: Skyclarys
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2023
Details:
Zurzuvae (zuranolone), the first and only oral, once-daily, 14-day treatment course, has shown to provide rapid improvements in depressive symptoms at Day 15 and as early as Day 3 for women with PPD.
Lead Product(s): Zuranolone
Therapeutic Area: Psychiatry/Psychology Product Name: Zurzuvae
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sage Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
